Last reviewed · How we verify
DAM
DAM is a dopamine agonist that acts on dopamine receptors in the brain.
DAM is a dopamine agonist that acts on dopamine receptors in the brain. Used for Parkinson's disease, Restless leg syndrome.
At a glance
| Generic name | DAM |
|---|---|
| Also known as | Dexamethasone-Allantoin-Metronidazole (DAM) Solution |
| Sponsor | Beijing Bozhiyin T&S Co., Ltd. |
| Drug class | Dopamine agonist |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Dopamine agonists like DAM mimic the action of dopamine in the brain, which can help regulate movement and other functions. This can be particularly beneficial for individuals with Parkinson's disease or restless leg syndrome.
Approved indications
- Parkinson's disease
- Restless leg syndrome
Common side effects
- Nausea
- Dizziness
- Headache
Key clinical trials
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Postoperative Pain After Single vs Multiple-Visit Root Canal Treatment in Diabetic Patients (NA)
- Evaluating Postoperative Pain and Antibacterial Effect of Ultrasonic and 980 nm Diode Laser Combination (NA)
- Clinical Performance of Printed Hybrid Resin in Indirect Restorations (NA)
- This Clinical Trial Aims to Compare the Effectiveness of Two Intra-pulpal Cryotherapy Techniques-Endo-ice and Ice Sticks-in Decreasing Intra-operative Pain and Enhancing the Success of Local Anesthesia During Pulpectomy of Mandibular Molars With Symptomatic Irreversible Pulpitis. (NA)
- Increasing HIV/STI Home Testing Via a Digital Intervention Among Black Women (NA)
- Gingival Crevicular Fluid Biomarkers and Healing After Root Canal Treatment in Asymptomatic Apical Periodontitis
- HEMA-free Universal Adhesives for Restoring Non-carious Cervical Lesions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAM CI brief — competitive landscape report
- DAM updates RSS · CI watch RSS
- Beijing Bozhiyin T&S Co., Ltd. portfolio CI